Filing Flows

Filing Flows › Companies › Zentalis Pharmaceuticals › Cash flow

Zentalis Pharmaceuticals cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$37.2M in Q2 2026 · −$128M over twelve months

Operating cash flow−$37.2M
Free cash flow−$37.2M

Analysis

In Q2 2026, Zentalis Pharmaceuticals generated −$37.2M of operating cash flow. That is $2.5M less than in Q2 2025 (−$34.7M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$128M; the largest uses were operating cash flow ($128M), other financing ($6.0M), capital spending ($34K); besides operations, cash came from other investing ($121M), shares issued ($511K); the cash balance fell by $12.8M.

Operating cash flow was −$37.2M against net income of −$42.3M. The largest differences: stock-based pay +$3.2M, payables +$2.3M, prepaid and other assets −$367K.

Free cash flow

Zentalis Pharmaceuticals: free cash flow by quarterZentalis Pharmaceuticals: free cash flow by quarter−$44.0MQ3 2024−$39.7MQ4 2024−$32.6MQ1 2025−$34.7MQ2 2025−$27.0MQ3 2025−$30.9MQ4 2025−$33.0MQ1 2026−$37.2MQ2 2026
Operating cash flow less capital spending.
Zentalis Pharmaceuticals: operating cash flow against capital spendingZentalis Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending−$44.0M$0Q3 2024−$39.7M$0Q4 2024−$32.6M$0Q1 2025−$34.7M$0Q2 2025−$27.0M$0Q3 2025−$30.9M$0Q4 2025−$33.0M$34KQ1 2026−$37.2M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$37.2M, Capital spending $0.

Capital allocation, year by year

Zentalis Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearZentalis Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingBuybacksFY2021: Operating cash flow −$154MFY2021: Shares issued $179MFY2021: Capital spending −$6.1M$179MFY2021FY2022: Operating cash flow −$164MFY2022: Shares issued $260MFY2022: Capital spending −$2.5M$260MFY2022FY2023: Operating cash flow −$208MFY2023: Shares issued $237MFY2023: Capital spending −$583K$237MFY2023FY2024: Operating cash flow −$171MFY2024: Shares issued $8KFY2024: Asset sales $65KFY2024: Capital spending −$221K$73KFY2024FY2025: Operating cash flow −$125MFY2025: Shares issued $5.7MFY2025: Asset sales $698KFY2025: Buybacks −$10.0M$6.4MFY2025
Over these 5 years operating cash flow totalled −$822M; the largest uses were operating cash flow ($822M) and buybacks ($10.0M). Cash-flow statements as filed.

Where the cash came from and went

Zentalis Pharmaceuticals: sources (+) and uses (−) of cash, Q2 2026Zentalis Pharmaceuticals: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$37.2MOther investing$30.0MCash drawn (+) / kept (−)$7.1MShares issued$65K
Zentalis Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q2 2026Zentalis Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$128MOther investing$121MCash drawn (+) / kept (−)$12.8MOther financing−$6.0MShares issued$511KAsset & business sales$129KCapital spending−$34K

From profit to cash

Zentalis Pharmaceuticals: net income to operating cash flow, Q2 2026Zentalis Pharmaceuticals: net income to operating cash flow, Q2 2026Net income−$42.3MDepreciation & amortization$152KStock-based pay$3.2MPayables$2.3MPrepaid and other assets−$367KOperating cash flow−$37.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$37.2M—$65K$7.1M−$37.2M
Q1 2026−$33.0M−$34K$331K$4.1M−$33.0M
Q4 2025−$30.9M——$3.1M−$30.9M
Q3 2025−$27.0M—$115K−$1.5M−$27.0M
Q2 2025−$34.7M——$4.3M−$34.7M
Q1 2025−$32.6M—$189K−$8.0M−$32.6M
Q4 2024−$39.7M——$7.4M−$39.7M
Q3 2024−$44.0M—$92K−$4.3M−$44.0M

Zentalis Pharmaceuticals: income statement and cash flow

Zentalis Pharmaceuticals, Q4 2024: revenue $26.9M, operating margin -185.6%. The chart follows the revenue to costs, profit and cash.

Zentalis Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.